OBJECTIVES::  To estimate and compare the long-term cost per responder based on the American College of Rheumatology outcomes (ACR 20/50/70) following 48 weeks of psoriatic arthritis (PsA) treatment with secukinumab relative to adalimumab. METHODS:: The cost per responder for each treatment was estimated by dividing the drug acquisition cost for the course of treatment with its response rate. Drug costs were estimated using the public price approved by Brazilian health authority and the number of doses required for 48 weeks. The long-term response rates were estimated using a Matching-Adjusted Indirect Comparison (MAIC) technique based on the data from FUTURE 2 and ADEPT clinical trials of secukinumab and adalimumab, respectively. RESULTS::  The MAIC analysis showed that ACR (20/50/70) response rates were higher for secukinumab 150mg and 300mg compared to adalimumab at 48 weeks. ACR 20 response rates were 80%, 74% and 56% ACR 50 response rates were 57%, 61% and 44%, whereas the ACR 70 response rates were 32%, 43% and 30% for secukinumab 150mg, secukinumab 300 mg and adalimumab respectively. Among PsA patients, costs per ACR20 responder were BRL58,686, BRL127,092 and BRL158,297, the costs per ACR50 responder were BRL81,781, BRL152,160 and BRL203,867 and the costs per ACR70 responder were BRL144,396, BRL217,847 and BRL299,005 for secukinumab 150mg, secukinumab 300mg and adalimumab respectively. The sensitivity analysis confirmed findings with even more favorable results for secukinumab. CONCLUSIONS::  The long term cost per responder for all ACR outcomes at 48 weeks were consistently lower for secukinumab (150,300mg) vs. adalimumab. These findings indicate that it is more efficient to treat PsA patients with secukinumab vs. adalimumab. In addition, with a given budget, more PsA patients could be effectively treated in Brazil versus adalimumab, due to the cost-offsets especially in biologic-naïve patients treated with secukinumab 150mg.